AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Original) A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)



(I)

wherein R^1 is a C_2-C_6 alkyl group or the formula (II)



(II)

wherein R^2 is a hydrogen atom or an acetyl group and R^3 is a C_1-C_6 alkyl group, a cycloalkyl group or



wherein R^4 and R^5 are each independently a hydrogen atom or a C_1-C_6 alkyl group, and in



of the formula (II), R^2 and R^3 may be linked to each other to form



wherein R^6 is a hydrogen atom or a C_1-C_6 alkyl group;





wherein R^7 and R^8 are each independently a hydrogen atom or a C_1-C_4 alkyl group,



wherein R^9 and R^{10} are each independently a hydrogen atom or a C_1-C_4 alkyl group,



wherein R^{11} is a hydrogen atom or a C_1-C_4 alkyl group; and



wherein R^{12} and R^{13} are each independently a C_1-C_4 alkyl group or may be linked to each other to form

wherein n is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,



wherein R^{14} is a hydrogen atom or a C_1-C_4 alkyl group,



wherein R^{15} is a hydrogen atom or an aralkyl group, or

provided that when



and R^7 should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.

2. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a compound of the formula (Ia)



(Ia)

wherein $R^{1'}$ is a C_2-C_6 alkyl group or the formula (II)'



(II)'

wherein R^2 is a hydrogen atom or an acetyl group, and $R^{3'}$ is a C_1-C_6 alkyl group or



wherein R^4 and R^5 are each independently a hydrogen atom or a C_1-C_6 alkyl group, and in



of the formula (II)', R^2 and $R^{3'}$ may be linked to each other to form



wherein R^6 is a hydrogen atom or a C_1-C_6 alkyl group;

$R^{9'}$ and $R^{10'}$ are each independently a C_1-C_4 alkyl group; and



wherein $R^{15'}$ is an aralkyl group, or

3. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)



(I b)

wherein $R^{1"}$ is a C_2-C_6 alkyl group,



or



wherein R^6 is a hydrogen atom or a C_1-C_6 alkyl group; and
R^9 and R^{10} are each independently a hydrogen atom or a C_1-C_4 alkyl group.

4. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. (Currently Amended) The therapeutic agent of ~~any of claims 1-4~~ claim 1, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

6. (New) The therapeutic agent of claim 2, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

7. (New) The therapeutic agent of claim 3, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

8. (New) The therapeutic agent of claim 4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.